|
Myeloid Leukemia, Chronic
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
CIP2A is overexpressed in CML-CP patients, and its expression may promote CML pathogenesis.
|
25023053 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cancerous inhibitor of PP2A (p90/CIP2A) was recently characterized as an innovative oncoprotein in human malignancies. p90/CIP2A inhibited c-Myc-associated PP2A phosphatase activity to promote cell proliferation and tumor growth.
|
25086622 |
2014 |
|
Prostate carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
CIP2A mediates prostate cancer progression via the c-MYC signaling pathway.
|
25560487 |
2015 |
|
Malignant neoplasm of prostate
|
0.070 |
Biomarker
|
disease |
BEFREE |
CIP2A mediates prostate cancer progression via the c-MYC signaling pathway.
|
25560487 |
2015 |
|
Prostate carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
CIP2A was significantly elevated in all five PCa cell lines when compared to the RWPE-1 cells at both the messenger RNA (mRNA) and protein levels.
|
25636449 |
2015 |
|
Malignant neoplasm of prostate
|
0.070 |
Biomarker
|
disease |
BEFREE |
CIP2A was significantly elevated in all five PCa cell lines when compared to the RWPE-1 cells at both the messenger RNA (mRNA) and protein levels.
|
25636449 |
2015 |
|
Prostate carcinoma
|
0.080 |
Biomarker
|
disease |
BEFREE |
CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.
|
25965834 |
2015 |
|
Malignant neoplasm of prostate
|
0.070 |
Biomarker
|
disease |
BEFREE |
CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations.
|
25965834 |
2015 |
|
Squamous cell carcinoma of the head and neck
|
0.040 |
Biomarker
|
disease |
BEFREE |
CIP2A and DPPA4 copy number increase occurred at a relatively high frequency in human HNSCC patient samples.
|
26436875 |
2016 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancerous inhibitor of PP2A (CIP2A) is a recently characterized oncoprotein, which promotes cancer cell proliferation.
|
26560124 |
2015 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancerous inhibitor of PP2A (CIP2A) is a recently characterized oncoprotein, which promotes cancer cell proliferation.
|
26560124 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CIP2A is a tumor-associated autoantigen in lung cancer, which promote lung cancer proliferation partially through MKK4/7-JNK signaling pathway.
|
26560124 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancerous inhibitor of PP2A (CIP2A) is a human oncoprotein that regulates cancer cell viability and anchorage-independent growth and induces apoptosis.
|
27144172 |
2016 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancerous inhibitor of PP2A (CIP2A) is a human oncoprotein that regulates cancer cell viability and anchorage-independent growth and induces apoptosis.
|
27144172 |
2016 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cancerous inhibitor of PP2A (CIP2A) supports the activity of several critical cancer drivers (Akt, MYC, E2F1) and promotes malignancy in most cancer types via PP2A inhibition.
|
28174209 |
2017 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Cancerous inhibitor of PP2A (CIP2A) supports the activity of several critical cancer drivers (Akt, MYC, E2F1) and promotes malignancy in most cancer types via PP2A inhibition.
|
28174209 |
2017 |
|
Myeloid Leukemia, Chronic
|
0.040 |
Biomarker
|
disease |
BEFREE |
KIAA1524 (also termed CIP2A), an oncoprotein inhibiting PP2A, is associated with disease progression in chronic myeloid leukaemia and may be prognostic in cytogenetically normal acute myeloid leukaemia.
|
28340282 |
2017 |
|
Cytogenetically normal acute myeloid leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
KIAA1524 (also termed CIP2A), an oncoprotein inhibiting PP2A, is associated with disease progression in chronic myeloid leukaemia and may be prognostic in cytogenetically normal acute myeloid leukaemia.
|
28340282 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CIP2A plays an 'oncogenic nexus' in several cancer types to participate in the tumorigenic transformation and chemoresistance.
|
28534965 |
2017 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
CIP2A plays an 'oncogenic nexus' in several cancer types to participate in the tumorigenic transformation and chemoresistance.
|
28534965 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CIP2A expression was tightly associated with tumor size, depth of invasion and lymph node metastasis in 184 cases of cervical cancer.
|
28559983 |
2017 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
CIP2A expression was tightly associated with tumor size, depth of invasion and lymph node metastasis in 184 cases of cervical cancer.
|
28559983 |
2017 |
|
Secondary malignant neoplasm of lymph node
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
CIP2A expression was tightly associated with tumor size, depth of invasion and lymph node metastasis in 184 cases of cervical cancer.
|
28559983 |
2017 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
CIP2A is an endogenous inhibitor of protein phosphatase 2A (PP2A), which can increase the migration and invasion of various cancer cells.
|
28560452 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Cancerous inhibitor of protein phosphatase 2A (CIP2A), an endogenous inhibitor of PP2A, is upregulated in many cancer cells, including non-small cell lung cancer (NSCLC) cells.
|
28813646 |
2017 |